Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
Status:
Completed
Trial end date:
2019-01-18
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is learn if carfilzomib can help control kidney
cancer. The safety of this drug will also be studied.
Carfilzomib is designed to block cancer cells from repairing themselves. If the cancer cells
cannot repair themselves, this may cause them to die.